All News about Lexaria Bioscience Corp
![](https://cdn.benzinga.com/files/images/story/2012/screenshot_2022-03-29_at_12.10.48_am.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2012/screenshot_2022-03-22_at_10.56.08_pm.png?width=1200&height=800&fit=crop)
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://cdn.benzinga.com/files/images/story/2012/screenshot_2022-03-16_at_10.24.01_pm.png?width=1200&height=800&fit=crop)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
Via AccessWire
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/screenshot_2022-03-10_at_12.29.53_am.png)
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Granted Important New Oral Nicotine Patent
March 08, 2022
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/screenshot_2022-03-07_at_10.45.57_pm.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/laboratory-5721287_1280.jpeg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/photo-1605040056130-38d9faad3534_3.jpeg?width=720)
Lexaria Bioscience (NASDAQ: LEXX) Optimistic of Positive Study Results
February 28, 2022
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/photo-1581594549595-35f6edc7b762_2.jpeg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.